SGLT2 inhibitors cut the risk for cardiovascular death and HF hospitalization in patients with HF, according to a study published in The Lancet. Muthiah Vaduganathan, MD, and colleagues reviewed data from 12,251 participants. SGLT2 inhibitors reduced composite cardiovascular death or first HF hospitalization (HR, 0.80), with consistent reductions for both components (cardiovascular death: HR, 0.88; first hospitalization for HF: HR, 0.74). In additional data from five trials (21,947 participants), SGLT2 inhibitors reduced the risk for composite cardiovascular death or hospitalization for HF, cardiovascular death, first HF hospitalization, and all-cause mortality.